Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FERRIC-HF III: Effect of IV Iron Isomaltoside on Cardiac Energetics in Iron-deficient Chronic Heart Failure
2017-004667-13Phase 4Unknown
- Sponsor
- King's College London
- Start
- Mar 2018
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, single-arm trial of ferric derisomaltose in chronic heart failure (CHF) and iron deficiency anemia (IDA), sponsored by King's College London. Primary endpoint: Cardiac PCr:ATP ratio. Status: unknown.
02
Drugs
ferric derisomaltose
03
Conditions
chronic heart failure (CHF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2017-004667-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004667-13.